Inovio Pharmaceuticals Reports Positive Data From Trial of COVID-19 Vaccine Candidate; Shares Rise Pre-Bell
08:39 AM EDT, 05/10/2021 (MT Newswires) -- Inovio Pharmaceuticals (INO) reported positive data from the phase 2 segment of a phase 2/3 trial evaluating its COVID-19 vaccine candidate INO-4800.
The biotech company said preliminary results show that INO-4800 was generally safe, well-tolerated, and immunogenic in all studied age groups in a larger population. Inovio said it will file preliminary phase 2 results and device data with the US Food and Drug Administration, and plans to conduct a phase 3 clinical trial for INO-4800 if approved.
Shares of Inovio Pharmaceuticals were up 2.2% in premarket activity.
Price: 7.00, Change: +0.15, Percent Change: +2.19